Comment from BioMarin Pharmaceutical, Inc.

Summary: BioMarin Pharmaceutical Inc. supports the FDA's efforts regarding Patient-Focused Drug Development (PFDD) meetings, noting their role in improving stakeholder engagement and clinical trial design. The company advocates for greater transparency from the FDA regarding how patient experience data specifically informs regulatory decision-making.